Quarterly Result2 Feb 2026, 06:44 pm
Corona Remedies Ltd Reports 15.0% Revenue Growth in Q3FY26
AI Summary
Corona Remedies Limited, a branded pharmaceutical formulation company, announced its unaudited results for the third quarter and nine months ended December 31, 2025. The company reported a consolidated revenue from operations of 342.42 Cr. for Q3FY26, representing a 15.0% year-over-year growth. The revenue for the nine months ended December 31, 2025, stood at 1,050.09 Cr., marking a 16.3% year-over-year growth. The Profit After Tax (PAT) for Q3FY26 and nine months FY26 was 55.56 Cr. and 154.08 Cr., respectively, with PAT growth of 23.7% and 30.7% year-over-year. Key financial metrics for the nine months FY26 include a Return on Equity (RoE) of 31.1%, Return on Capital Employed (ROCE) of 48.0%, and an OCF to EBITDA of 86.3%.
Key Highlights
- Revenue from operations for Q3FY26 grew by 15.0% year-over-year
- Revenue for nine months FY26 grew by 16.3% year-over-year
- PAT for Q3FY26 grew by 23.7% year-over-year
- PAT for nine months FY26 grew by 30.7% year-over-year
- Strong performance in women's healthcare, cardio-diabeto, pain management, urology, and other therapeutic areas